L M Allen|P J Creaven - JoVE Visualize

Showing results (91-100 of 115) with videos related to

Pageof 12

Sort By:

Research Communications in Chemical Pathology and Pharmacology|September 1, 1980

Immunological modification of adriamycin cardiotoxicityN Savaraj, L M Allen, C Sutton, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1989

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five daysP J Creaven, D E Brenner, J W Cowens, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1982

Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?L M Allen, F Tejada, A D Okonmah, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1994

Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimenP J Creaven, Y M Rustum, N J Petrelli, et al.

Cancer Research|June 1, 1978

Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouseZ P Pavelic, C W Porter, L M Allen, et al.

Journal of Pediatric and Adolescent Gynecology|June 23, 2009

Menstrual suppression for adolescents with developmental disabilitiesI Savasi, R F Spitzer, L M Allen, et al.

Archives of Dermatology|March 1, 1984

A double-blind study of prazosin in the treatment of Raynaud's phenomenon in sclerodermaR S Surwit, R S Gilgor, L M Allen, et al.

Cancer Treatment Reports|May 1, 1981

Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575, generation I)R H Creech, C R Mehta, M Cohen, et al.

Brain Injury|November 20, 2001

Effort has a greater effect on test scores than severe brain injury in compensation claimantsP Green, M L Rohling, P R Lees-Haley, et al.

Cancer Research|November 1, 1981

Inhibition of cell cycle progression of human pancreatic carcinoma cells in vitro by L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, Acivicin (NSC 163501)R A Meck, K J Clubb, L M Allen, et al.

Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:

Pageof 12

Research Communications in Chemical Pathology and Pharmacology|September 1, 1980

Immunological modification of adriamycin cardiotoxicityN Savaraj, L M Allen, C Sutton, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1989

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five daysP J Creaven, D E Brenner, J W Cowens, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1982

Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?L M Allen, F Tejada, A D Okonmah, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1994

Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimenP J Creaven, Y M Rustum, N J Petrelli, et al.

Cancer Research|June 1, 1978

Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouseZ P Pavelic, C W Porter, L M Allen, et al.

Journal of Pediatric and Adolescent Gynecology|June 23, 2009

Menstrual suppression for adolescents with developmental disabilitiesI Savasi, R F Spitzer, L M Allen, et al.

Archives of Dermatology|March 1, 1984

A double-blind study of prazosin in the treatment of Raynaud's phenomenon in sclerodermaR S Surwit, R S Gilgor, L M Allen, et al.

Cancer Treatment Reports|May 1, 1981

Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575, generation I)R H Creech, C R Mehta, M Cohen, et al.

Brain Injury|November 20, 2001

Effort has a greater effect on test scores than severe brain injury in compensation claimantsP Green, M L Rohling, P R Lees-Haley, et al.

Cancer Research|November 1, 1981

Inhibition of cell cycle progression of human pancreatic carcinoma cells in vitro by L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, Acivicin (NSC 163501)R A Meck, K J Clubb, L M Allen, et al.

Pageof 12